Prestige Biopharma Signs Strategic MOU with Charles River Laboratories
Prestige Biopharma and Prestige Biologics have signed a strategic memorandum of understanding (MOU) with Charles River Laboratories International (Charles River) to collaborate in the areas of biopharmaceutical development, testing, analysis, and integrated manufacturing.
On the 22nd of last month, at the 'BIO USA 2026' held in San Diego, USA, Prestige Biopharma and Prestige Biologics signed a strategic memorandum of understanding (MOU) with Charles River Laboratories International (Charles River). A strategic MOU signing ceremony for Prestige Biopharma was held.
View original imageAccording to Prestige Biopharma on July 2, Charles River, established in 1947, is a global life sciences service company headquartered in Wilmington, Massachusetts, USA, with approximately 20,000 employees working at more than 120 facilities in over 20 countries worldwide. As of last year, its annual revenue reached about USD 4.02 billion (approximately KRW 6.2 trillion), and over the past five years, it has supported the development of around 80% of the drugs approved by the U.S. Food and Drug Administration (FDA).
The core of this agreement is the combination of both companies' specialized services throughout the entire new drug development cycle and the exchange of customer networks. Prestige Biopharma will enhance its antibody drug development capabilities by utilizing Charles River’s global testing, analysis, and quality control services. At the same time, its subsidiary Prestige Biologics plans to leverage Charles River’s global network to connect with overseas projects that require entry into the manufacturing stage, thereby actively expanding global GMP manufacturing and CDMO order opportunities, including in North America.
Specific areas of collaboration for biopharmaceutical development support include: ▲ development and validation of analytical methods ▲ quality control (QC) and release testing ▲ biological and viral safety and cell line characterization ▲ GLP-compliant toxicity studies ▲ pharmacokinetic (PK) and pharmacodynamic (PD) studies. Furthermore, both companies plan to strengthen their presence in the global market through joint marketing activities, such as participating in major industry conferences, hosting seminars, and publishing technical white papers.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Prestige Biopharma representative stated, "This strategic collaboration with Charles River, a global CRO, marks an important milestone in connecting our antibody development and manufacturing capabilities with a broader global client network. By combining our core expertise, we aim to maximize efficiency in biopharmaceutical development and actively expand our CDMO order pipeline in key markets."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.